HK1201046A1 - Methods of treating ophthalmic diseases - Google Patents

Methods of treating ophthalmic diseases

Info

Publication number
HK1201046A1
HK1201046A1 HK15101561.0A HK15101561A HK1201046A1 HK 1201046 A1 HK1201046 A1 HK 1201046A1 HK 15101561 A HK15101561 A HK 15101561A HK 1201046 A1 HK1201046 A1 HK 1201046A1
Authority
HK
Hong Kong
Prior art keywords
methods
ophthalmic diseases
treating ophthalmic
treating
diseases
Prior art date
Application number
HK15101561.0A
Other languages
English (en)
Chinese (zh)
Inventor
家-揚．林
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of HK1201046A1 publication Critical patent/HK1201046A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15101561.0A 2007-03-09 2015-02-12 Methods of treating ophthalmic diseases HK1201046A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89418107P 2007-03-09 2007-03-09
US12/041,581 US20090022728A1 (en) 2007-03-09 2008-03-03 Methods of treating ophthalmic diseases

Publications (1)

Publication Number Publication Date
HK1201046A1 true HK1201046A1 (en) 2015-08-21

Family

ID=39760152

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101561.0A HK1201046A1 (en) 2007-03-09 2015-02-12 Methods of treating ophthalmic diseases

Country Status (15)

Country Link
US (1) US20090022728A1 (fr)
EP (1) EP2134751A2 (fr)
JP (2) JP5964004B2 (fr)
KR (2) KR101259225B1 (fr)
CN (2) CN101687922B (fr)
AU (1) AU2008224600B2 (fr)
BR (1) BRPI0808711A2 (fr)
CA (1) CA2680222C (fr)
HK (1) HK1201046A1 (fr)
IL (1) IL200528A0 (fr)
MX (1) MX2009009636A (fr)
NZ (1) NZ579273A (fr)
RU (1) RU2434639C2 (fr)
TW (1) TWI449535B (fr)
WO (1) WO2008110885A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
AU2015200604B2 (en) * 2007-10-05 2016-10-27 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
CA2701790A1 (fr) * 2007-10-05 2009-04-16 Ac Immune S.A. Utilisation d'anticorps anti-amyloides beta humanises dans les maladies oculaires
US9403902B2 (en) * 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
PE20091449A1 (es) * 2007-12-11 2009-10-07 Glaxo Group Ltd Proteinas de union a antigenos
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
US20140050733A1 (en) 2011-02-07 2014-02-20 Dale B. Schenk Apoe immunotherapy
RU169012U1 (ru) * 2016-08-08 2017-03-01 Дмитрий Викторович Давыдов Электрод для электростимуляции зрительного нерва и зрительных путей и контроля физиологических параметров орбитальных структур глаза
WO2018200620A1 (fr) * 2017-04-25 2018-11-01 National Cheng Kung University Utilisation d'antagonistes de l'il-20 pour le traitement de maladies oculaires
MX2022007114A (es) * 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025516A2 (fr) * 2003-09-12 2005-03-24 The Regents Of The University Of California Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente
EP1633786A4 (fr) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide g(b)-amyloide et compositions les comprenant
US20060121039A1 (en) * 2004-12-07 2006-06-08 Alcon, Inc. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration
EP2298807A3 (fr) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Anticorps anti peptide amyloide beta, et leurs procedes d' utilisation
WO2006039327A2 (fr) * 2004-10-01 2006-04-13 Merck & Co., Inc. Procedes de traitement ou prophylaxie de maladies amyloidogeniques de l'oeil ou du nerf optique
AU2006211625A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
RU2551782C2 (ru) * 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
PL2046833T3 (pl) * 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
EP2074145B1 (fr) * 2006-10-02 2017-08-16 AC Immune S.A. Anticorps humanise contre amyloide-beta

Also Published As

Publication number Publication date
CA2680222A1 (fr) 2008-09-18
CN101687922B (zh) 2014-06-11
KR101259225B1 (ko) 2013-04-30
TWI449535B (zh) 2014-08-21
JP2009062358A (ja) 2009-03-26
MX2009009636A (es) 2009-12-11
CA2680222C (fr) 2013-10-08
CN101687922A (zh) 2010-03-31
NZ579273A (en) 2012-03-30
RU2009133789A (ru) 2011-03-20
KR20090119990A (ko) 2009-11-23
EP2134751A2 (fr) 2009-12-23
WO2008110885A3 (fr) 2009-01-15
IL200528A0 (en) 2010-04-29
BRPI0808711A2 (pt) 2014-08-12
WO2008110885A2 (fr) 2008-09-18
AU2008224600B2 (en) 2011-09-29
AU2008224600A1 (en) 2008-09-18
TW200900079A (en) 2009-01-01
CN104027803A (zh) 2014-09-10
US20090022728A1 (en) 2009-01-22
RU2434639C2 (ru) 2011-11-27
KR20120054105A (ko) 2012-05-29
JP2015038109A (ja) 2015-02-26
JP5964004B2 (ja) 2016-08-03

Similar Documents

Publication Publication Date Title
HK1201046A1 (en) Methods of treating ophthalmic diseases
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
HK1217763A1 (zh) 用於治療疾病的方法
EP2432476A4 (fr) Procédés de traitement ou de prévention de maladies ophtalmologiques
EP2182983A4 (fr) Traitement de maladies amyloïdogéniques
EP2176283A4 (fr) Methodes et compositions de traitement des maladies cerebrales
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
EP2134173A4 (fr) Traitement de maladies caracterisees par une inflammation
PL2056863T3 (pl) Leczenie chorób oczu
EP2509596A4 (fr) Composés et procédés de traitement de troubles oculaires
IL207687A0 (en) Method of treating ocular diseases by gene therapy
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
EP2341936A4 (fr) PROCÉDÉS POUR LE TRAITEMENT OU LA PRÉVENTION DES MALADIES ASSOCIÉES À IL-1ß
EP2026822A4 (fr) Traitement topique de maladies associées à la surface oculaire
HK1149545A1 (en) Compositions and methods for treating ophthalmic diseases
EP2403503A4 (fr) Méthodes permettant de traiter des maladies inflammatoires oculaires
PL2012814T3 (pl) Sposoby leczenia chorób autoimmunologicznych
HK1139334A1 (en) Method of treating demyelination diseases
EP2296682B8 (fr) Procédés de traitement de troubles ophtalmiques
EP2164494A4 (fr) Procédés de traitement
EP2262515A4 (fr) Utilisation de soja noir pour traiter des maladies ophtalmiques
EP2244702A4 (fr) Traitement de maladies neurales ou d'états neuraux
EP2117529A4 (fr) Procédés pour traiter des maladies présentant une régulation des ige altérée
ZA200906883B (en) Methods of treating ophthalmic diseases